These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17162252)

  • 1. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice.
    Hou G; Dick R; Abrams GD; Brewer GJ
    J Lab Clin Med; 2005 Nov; 146(5):299-303. PubMed ID: 16242529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
    Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
    Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
    Brewer GJ
    Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
    Hou G; Abrams GD; Dick R; Brewer GJ
    Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
    Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
    J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
    Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
    J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model.
    Brewer GJ; Dick R; Zeng C; Hou G
    J Inorg Biochem; 2006 May; 100(5-6):927-30. PubMed ID: 16321443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
    Brewer GJ
    J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate.
    Hou G; Dick R; Brewer GJ
    Exp Biol Med (Maywood); 2009 Jun; 234(6):662-5. PubMed ID: 19307461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
    Cox C; Teknos TN; Barrios M; Brewer GJ; Dick RD; Merajver SD
    Laryngoscope; 2001 Apr; 111(4 Pt 1):696-701. PubMed ID: 11359142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice.
    Osman AM; Nemnem MM; Abou-Bakr AA; Nassier OA; Khayyal MT
    Food Chem Toxicol; 2009 Oct; 47(10):2425-30. PubMed ID: 19577608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metallothionein acts as a cytoprotectant against doxorubicin toxicity.
    Kimura T; Fujita I; Itoh N; Muto N; Nakanishi T; Takahashi K; Azuma J; Tanaka K
    J Pharmacol Exp Ther; 2000 Jan; 292(1):299-302. PubMed ID: 10604962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrathiomolybdate is partially protective against hyperglycemia in rodent models of diabetes.
    Zeng C; Hou G; Dick R; Brewer GJ
    Exp Biol Med (Maywood); 2008 Aug; 233(8):1021-5. PubMed ID: 18480419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.
    Kim KK; Kawar NM; Singh RK; Lange TS; Brard L; Moore RG
    Gynecol Oncol; 2011 Jul; 122(1):183-9. PubMed ID: 21529906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-allylcysteine ameliorates doxorubicin toxicity in the heart and liver in mice.
    Mostafa MG; Mima T; Ohnishi ST; Mori K
    Planta Med; 2000 Mar; 66(2):148-51. PubMed ID: 10763589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of copper-lowering therapy with tetrathiomolybdate in medicine.
    Brewer GJ
    Expert Opin Investig Drugs; 2009 Jan; 18(1):89-97. PubMed ID: 19053885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.